UroGen Pharma Ltd. — Director's Dealing 2020

Jan 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-01-26

Reporting Person: Mullennix Stephen (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-26	Ordinary Shares	M	1666	—	Acquired	9349	Direct
2020-01-27	Ordinary Shares	S	684	$29.26	Disposed	8665	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-26	Restricted Stock Units (RSUs)	$	M	1666	Disposed		Ordinary Shares (1666)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.